m m 0 1 0 2 0 3 0 4 0 v e h i c l e b i d r x c 0 0 5 [ 5 ... · l o g [ r x c 0 0 5 ] ( m ) % i n...

1
Log [RXC005] (M) % inhibition -14 -12 -10 -8 -6 -4 -20 0 20 40 60 80 100 120 BTK WT BTK C481S -11 -10 -9 -8 -7 -6 -5 -4 0 20 40 60 80 100 120 Log [RXC005] (M) BTK WT BTK C481S % inhibition -12 -10 -8 -6 -4 0 20 40 60 80 100 120 log[RXC005] (M) % of activated B-cells (IgM-stimulated CD19+ CD69+ cells) -12 -10 -8 -6 -4 -20 0 20 40 60 80 100 120 log[RXC005] (M) % of activated B-cells (IgD-stimulated CD19+ CD69+ cells) pBTK BTK B-Actin γ γ α Cell line OCI-Ly10 (pIC 50 ) 8.2± 9.3±0.2 8.3±0.1 8.4±0.2 TMD8 (pIC 50 ) 8.3± 9.1±0.2 8.3 (N=2) 8.2 (N=2) IgM stimulation pBtk gapdh Btk 00251868 CLL Vehicle 200 nM RXC005 500 nM Ibrutinib Vehicle DC9 (+ control) 500 nM RXC005 100 nM RXC005 0 10 20 30 40 1.0 1.5 2.0 Days post last treatment RTV (Relative Tumour Volume) **** *** *** **** p<0.0001 *** p<0.001 0 20 40 60 Days Tumour volume (mm 3 ) Vehicle BID RXC005 [10mg/kg] BID RXC005 [50mg/kg] BID Ibrutinib [10mg/kg] QD 200 300 400 500 150 100 Treatment Regrowth 0 10 20 30 Treatment time (Days) Tumour volume (mm 3 ) Vehicle BID RXC005 10 mg/kg BID RXC005 50 mg/kg BID Ibrutinib 10mg/kg QD 200 300 400 500 150 100 **** **** p<0.0001 *** *** p<0.001 0 7 14 21 Treatment time (days) Tumour volume (mm 3 ) Vehicle RXC005 30mg/kg BID 100 200 400 RXC005 10mg/kg BID 800 1000 **** p<0.0001 **** ****

Upload: others

Post on 19-May-2020

2 views

Category:

Documents


0 download

TRANSCRIPT

Page 1: M m 0 1 0 2 0 3 0 4 0 V e h i c l e B I D R X C 0 0 5 [ 5 ... · L o g [ R X C 0 0 5 ] ( M ) % i n h i b i t i o n - 1 4 - 1 2 - 1 0 - 8 - 6 - 4 - 2 0 0 2 0 4 0 6 0 8 0 1 0 0 1 2

L o g [R X C 0 0 5 ] (M )

% i

nh

ibit

ion

-1 4 -1 2 -1 0 -8 -6 -4

-2 0

0

2 0

4 0

6 0

8 0

1 0 0

1 2 0

B T K W T

B T K C 4 8 1 S

-1 1 -1 0 -9 -8 -7 -6 -5 -4

0

2 0

4 0

6 0

8 0

1 0 0

1 2 0

L o g [R X C 0 0 5 ] (M )

B T K W T

B T K C 4 8 1 S

% i

nh

ibit

ion

-1 2 -1 0 -8 -6 -4

0

2 0

4 0

6 0

8 0

1 0 0

1 2 0

lo g [R X C 0 0 5 ] (M )

% o

f a

cti

va

ted

B-c

ell

s

(Ig

M-s

tim

ula

ted

CD

19

+ C

D6

9+

ce

lls

)

-1 2 -1 0 -8 -6 -4

-2 0

0

2 0

4 0

6 0

8 0

1 0 0

1 2 0

lo g [R X C 0 0 5 ] (M )

% o

f a

cti

va

ted

B-c

ell

s

(Ig

D-s

tim

ula

ted

CD

19

+ C

D6

9+

ce

lls

)

pBTK

BTK

B-Actin

γ γ

α

Cell line

OCI-Ly10 (pIC50) 8.2± 9.3±0.2 8.3±0.1 8.4±0.2

TMD8 (pIC50) 8.3± 9.1±0.2 8.3 (N=2) 8.2 (N=2)

IgM stimulation

pBtk

gapdh

Btk

00251868 CLL

Veh

icle

20

0 n

MR

XC

00

5

50

0 n

MIb

ruti

nib

Veh

icle

DC

9 (

+ co

ntr

ol)

50

0 n

MR

XC

00

5

10

0 n

MR

XC

00

5

0 1 0 2 0 3 0 4 01 .0

1 .5

2 .0

D a y s p o s t la s t t r e a t m e n t

RT

V (

Re

lati

ve

Tu

mo

ur

Vo

lum

e)

****

***

***

* * * * p < 0 .0 0 0 1

* * * p < 0 .0 0 1

0 2 0 4 0 6 0

D a y s

Tu

mo

ur

vo

lum

e (

mm

3)

V e h ic le B ID

R X C 0 0 5 [1 0 m g / k g ] B ID

R X C 0 0 5 [5 0 m g / k g ] B ID

Ib r u t in ib [1 0 m g / k g ] Q D

2 0 0

3 0 0

4 0 0

5 0 0

1 5 0

1 0 0T re a tm e n t R e g r o w th

0 1 0 2 0 3 0

T r e a t m e n t t im e (D a y s )

Tu

mo

ur

vo

lum

e (

mm

3)

V e h ic le B ID

R X C 0 0 5 1 0 m g / k g B ID

R X C 0 0 5 5 0 m g / k g B ID

Ib r u t in ib 1 0 m g / k g Q D

2 0 0

3 0 0

4 0 0

5 0 0

1 5 0

1 0 0

****

* * * * p < 0 .0 0 0 1

***

* * * p < 0 .0 0 1

0 7 1 4 2 1

T r e a t m e n t t im e (d a y s )

Tu

mo

ur

vo

lum

e (

mm

3)

V e h ic le

R X C 0 0 5 3 0 m g / k g B ID

1 0 0

2 0 0

4 0 0

R X C 0 0 5 1 0 m g / k g B ID

8 0 0

1 0 0 0

* * * * p < 0 .0 0 0 1

****

****